Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

Disclosure Statement of Financial Interest
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Can we prevent stent restenosis after coronary stent implantation
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
Journal : Evidence Review PCI : Role of FFR Dr Binjo J Vazhappilly SR Cardiology MCH Calicut.
Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
New ESC/EACTS guidelines on myocardial revascularisation Indications for coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention.
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Journal Club Jeffrey P Schaefer, MD April 16, 2007.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Treatment strategies for “stable” CAD patients: COURAGE, OAT, SWISSI II, VIAMI in perspective Pierfrancesco Agostoni, MD Antwerp Cardiovascular Institute.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Total Occlusion Study of Canada (TOSCA-2) Trial
Copyright © 2014 American Medical Association. All rights reserved.
William E. Boden, MD, FACC, FAHA
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Clinical need for determination of vulnerable plaques
Background Over PCIs per year for stable angina
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Atrial Fibrillation and PCI
Complex Revascularization: Geographic Variations in Practice
Achieving Long-Term Protection Post-MI
New Perspectives in AF and PCI: Implications for the Practicing Physician.
What Has Been Tried and What Is True?
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
Recurrent Angina: New Tools for an Old Problem
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Terms of Use. Terms of Use.
Considerations for Percutaneous Coronary Intervention (PCI)
Section 5: Intervention and drug therapy
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.
Nat. Rev. Cardiol. doi: /nrcardio
(p = 0.32 for noninferiority)
Typical Patient Presentation
(p < for noninferiority)
O.L.Reuchlin gebruik van CT binnen de cardiogie
(p = for noninferiority)
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
The American College of Cardiology Presented by Dr. A. Abazid
Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.
FIELD: Primary outcome
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Javier Escaned et al. JCIN 2018;11:
Section C: Clinical trial update: Oral antiplatelet therapy
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Stable CAD Percutaneous Coronary Intervention (PCI) vs Medical Management Pre-COURAGE

What Can Be Achieved With OMT in SIHD COURAGE Primary End Point

Are COURAGE Trial Patients Generalizable to Contemporary Clinical Practice?

COURAGE Coronary Angiographic Outcomes

Need for Subsequent Revascularization 7 y of Follow-up*

COURAGE Primary End Point of Death and Nonfatal MI by Core Laboratory Angiographic Severity No Difference

FAME 2 Trial Fractional Flow Reserve (FFR)-Guided PCI vs OMT in Stable Coronary Disease

Summary Odds Ratios (ORs) (n = 23 Trials) Angina Relief Stratified by Duration of Follow-up and Recruitment Period

Outcomes in Combined Direct and Indirect Analysis of 61 Randomized Trials in Nonacute CAD, HR (95% CI) n = 25,388 patients

Review Article -- Initial Coronary Stent Implantation With MT vs MT Alone for Stable CAD Meta-analysis of Randomized Controlled Trials

Why PCI May Not Reduce Long-term Events in Stable CAD

2011 ACCF/AHA/SCAI PCI Guidelines

Conclusions 2014

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)